Generation Bio Co. (GBIO) Research

Generation Bio Co. is a biotechnology firm focused on genetic therapies, working to devise treatments for both uncommon and widespread diseases. The company's current development pipeline includes multiple projects, with a particular emphasis on addressing rare and prevalent conditions affecting the liver and retina. Additionally, it directs its research towards disorders of skeletal muscle, the central nervous system, and oncology. The enterprise, which was initially established as Torus Therapeutics, Inc., adopted its current name, Generation Bio Co., in November 2017. Incorporated in 2016, its main operations are based in Cambridge, Massachusetts.

Market snapshot

Symbol
GBIO
Price
$5.34
Day change
0.00%
Market cap
$36.0M
P/E ratio
-0.57x
52-week range
3.004-7.516
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$5.25

Peer companies

  • Boundless Bio, Inc. (BOLD)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Celularity Inc. (CELU)
  • Evaxion Biotech A/S (EVAX)
  • Jasper Therapeutics, Inc. (JSPR)
  • Mural Oncology plc (MURA)
  • NextCure, Inc. (NXTC)
  • Q32 Bio Inc. (QTTB)

Recent insider activity

  • Atlas Venture Fund X, L.P. — U-Tender (60 shares) on 2026-02-09
  • Stehman-Breen Catherine — D-Return (6000 shares) on 2026-02-09
  • Stehman-Breen Catherine — D-Return (3000 shares) on 2026-02-09
  • Stehman-Breen Catherine — D-Return (5200 shares) on 2026-02-09
  • Stehman-Breen Catherine — D-Return (1500 shares) on 2026-02-09

Open Generation Bio Co. (GBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.